Navigation Links
JAZZ PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2013 FINANCIAL RESULTS
Date:8/6/2013

are not historical facts.  These forward-looking statements are based on Jazz Pharmaceuticals' current expectations and inherently involve significant risks and uncertainties.  Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with maintaining and increasing sales of and revenue from Xyrem, such as the potential introduction of generic competition and changed or increased regulatory restrictions on or requirements with respect to Xyrem, as well as similar risks related to effectively commercializing the company's other marketed products, including Erwinaze and Prialt; protecting and expanding the company's intellectual property rights; obtaining appropriate pricing and reimbursement for the company's products in an increasingly challenging environment; ongoing regulation and oversight by U.S. and non-U.S. regulatory agencies; dependence on key customers and sole source suppliers, including the risk that the company may not be able to timely resolve potential product supply shortages and meet product demand; the difficulty and uncertainty of pharmaceutical product development and the uncertainty of clinical success and regulatory approval; the company's ability to identify and acquire, in-license or develop additional products or product candidates to grow its business; and possible restrictions on the company's ability and flexibility to pursue certain future opportunities as a result of its substantial outstanding debt obligations; as well as risks related to future opportunities and plans, including the uncertainty of expected future financial performance and results; and those other risks detailed from time-to-time under the caption "Risk Factors" and elsewhere in Jazz Pharmaceuticals plc's Securities and Exchange Commission filings and reports (Commission File No
'/>"/>
SOURCE Jazz Pharmaceuticals plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. Cumberland Pharmaceuticals Reports Second Quarter Financial Results
2. Inovio Pharmaceuticals Responds to Market Activity
3. UPCOMING DEADLINE: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Vanda Pharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of August 24, 2013 to Seek a Lead Plaintiff Position
4. Valeant Pharmaceuticals International, Inc. Completes Acquisition Of Bausch + Lomb
5. Avanir Pharmaceuticals to Participate in Two Conferences in August
6. Imprimis Pharmaceuticals, Inc. to Present at the Southern California Investor Conference on Thursday, August 8, 2013 at the Island Hotel in Newport Beach, CA. The presentation is scheduled to begin at 11 a.m. ET / 8 a.m. PT
7. AcelRx Pharmaceuticals to Present at Canaccord Genuity 33rd Annual Growth Conference
8. Isis Pharmaceuticals Reports Data From a Phase 2 Study of Isis-CRP Rx in Patients with Rheumatoid Arthritis
9. Intercept Pharmaceuticals to Present at the Wedbush Securities Life Sciences Management Access Conference
10. GW Pharmaceuticals Announces Results of MS Spasticity Study Confirming Sativex Has No Long-Term Negative Effect on Cognition
11. GW Pharmaceuticals plc Reports 2013 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 28, 2014 OmPrompt ... Millionen £ investiert hat, um die weltweite ... Pharma- und Logistikbranche zu erfüllen. Albion wird ... (Photo: http://photos.prnewswire.com/prnh/20140728/697982 ) ... sein beschleunigtes Wachstum mit Investitionen in seine ...
(Date:7/28/2014)... VILLAGE, Nev. , July 28, 2014 PDL ... that the Company will release its second quarter 2014 financial ... August 11, 2014, after market close. PDL,s management will host ... Eastern Time to discuss the financial results.  A slide presentation ... link on the PDL website. Conference Call Details ...
(Date:7/28/2014)... Germany and LONDON ... , Collaboration aims to create and commercialize companion ... the use of IRESSA  for non-small cell lung cancer ... QIAGEN,s FDA-approved  therascreen   EGFR test and is planned to run on ... instruments  Project enabled by AstraZeneca master framework ...
Breaking Medicine Technology:OmPrompt erhält Finanzierung für Marktexpansion von Kundenautomatisierungsmanagement 2PDL BioPharma to Announce Second Quarter 2014 Financial Results on August 11, 2014 2QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 2QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 3QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 4QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 5QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 6
... Consumer Healthcare Products Association (CHPA) released the following ... passing a real-time, stop-sale system that allows law-abiding ... pseudoephedrine (PSE), while stopping sales that exceed the ... real-time, stop-sale system is a victory for law-abiding ...
... HeartWare International, Inc. (NASDAQ: HTWR ... miniaturized circulatory support technologies that are revolutionizing the treatment ... Godshall is scheduled to make an investor presentation at ... Eastern Time on Wednesday, June 22, 2011.  The conference ...
Cached Medicine Technology:HeartWare to Present at the Wells Fargo 2011 Healthcare Conference 2
(Date:7/28/2014)... new study, published in the July, 2014, issue ... Institute by Northwestern Medicine researchers, sheds new ... popularity of endoscopic resection in the treatment of ... more traditional surgical resection, while more invasive, provided ... survival rate for patients than endoscopic resection, which ...
(Date:7/28/2014)... Smart phones and mobile devices are on the cusp ... apps capable of providing everything from cardiac measurements to ... to medical treatment and control costs, several health law ... of Medicine (NEJM) report that more oversight is ... to ensure consumer confidence and safety. Out of some ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 A young ... to the all-too-often stories in the media today about ... occur in a matter of minutes in a hot ... to the Office of Emergency Medical Services at NHTSA. ... app for smartphones. Realizing that it’s all too easy ...
(Date:7/28/2014)... Abington, PA (PRWEB) July 28, 2014 ... solutions provider for the healthcare industry, went live in ... and surpassed the basic standards of excellence that comprise ... specifically for excellence in Healthcare. , “What pleases me ... both the content and usability categories,” said Joshua Snow, ...
(Date:7/28/2014)... 2014 Irresistible infants have met their match with ... The online gifting company specializes in homemade chicken noodle soup and ... Baby package starts with home-from-the-hospital essentials every new parent will love:, ... 6 rolls , 6 cookies , a ... is ready to heat and eat upon delivery, so parents can ...
Breaking Medicine News(10 mins):Health News:Study helps compare risks of treatments for early esophageal cancer 2Health News:Study helps compare risks of treatments for early esophageal cancer 3Health News:Booming mobile health app market needs more FDA oversight for consumer safety, confidence 2Health News:'Precious Cargo' App Released to Help Save Babies from the Dangers of Being Accidentally Left Behind in Hot Cars 2Health News:Abington Health Website Named Best in Class 2Health News:Spoonful of Comfort Announces "New Baby" Gift Package 2
... genetic links, but urge further study , WEDNESDAY, Oct. ... that might be associated with autism have been identified ... a single-letter change on chromosome 5 near a gene ... the growth of neurons and their long progressions, called ...
... 7 Each year, an estimated 800,000 ... in which the victims survive, but their lives, and ... Brain injury victims can suffer from a multitude of ... depression and sleep disturbances. , Careforward , ...
... Crawford & Company,s (NYSE: CRDA ; CRDB) ... under the brand name of Broadspire, a Crawford company, ... , Crawford (NYSE: CRDA ; CRDB), the world,s ... latest expansion of the Broadspire brand at the Federation ...
... Healthcare, one of the nation,s first and leading providers ... nephrology research, today announced their sponsorship of the National ... , The Author,s Luncheon is San Francisco,s premier ... captivated by the fascinating stories, wit and humor of ...
... , BOCA RATON, Fla., Oct. 7 Coverall Health-Based Cleaning ... announced it has been recognized as one of the ... Franchising Initiative (NMFI) for the third year in a ... "Franchising Today" section of USA Today, the national daily ...
... Henry Ford Hospital have identified tumor-suppressing genes that may ... survival for laryngeal cancer patients than current standards. ... specific receptor 1) gene and the HIC1 (hypermethylated in ... and shorter survival, respectively, for patients with the disease. ...
Cached Medicine News:Health News:Potential Pieces of Autism Puzzle Revealed 2Health News:Mingling, Martinis & Mysterious Murder Masquerade at the Whitney to Benefit Carnival of Care 2Health News:Crawford & Company's Broadspire Unit Continues Its European Expansion 2Health News:Satellite Healthcare Partners With the National Kidney Foundation for the 21st Annual San Francisco Author's Luncheon 2Health News:Coverall Named Among '50 Top Franchises for Minorities' for Third Consecutive Year 2Health News:Genes signal late-stage laryngeal cancer, poorer outcome 2
... The Finnpipette Digital Multichannel, ... even lighter work of routine ... all these advanced features: Soft-touch ... micro volume pipetting (0.5-10ul models), ...
... Unique to the Medtronic Hall, the aortic and ... In the aortic position, the disc opens to ... valve opens to 70 to minimize regurgitation. Designed ... the surgeon to align the leading edge of ...
... Pipettor , , The Shortyavailable with both ... how our face-to-face relationship with the scientific community ... make pipetting easier and more effective., Shorter ... Gets you closer to the working area ...
The Biopette E has a comfortable, ergonomic design. Fully motorized piston drive. Virtually eliminates pipetting forces. User-friendly operator interface. Simple, precise volume setting. Rechargelabl...
Medicine Products: